logo-loader
viewImugene Ltd

Imugene pounces on material acquisition

Imugene is an immuno-oncology company focused on gastric cancer.

1528157428_acquisition-350.jpg
The company's shares are in pre-open

Imugene Ltd (ASX:IMU) has been a strong performer on the ASX, last trading at 3 cents, or more than double its value in January 2018.

The company recently appointed Ms Leslie Chong as managing director. As CEO, Ms Chong achieved various important milestones in both the clinical and corporate fronts.

The next steps for Imugene will be interesting, with the company this morning entering a trading halt pending details of a material acquisition, and subsequent capital raising.

Currently, Imugene's lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer.

The halt will remain in place until the opening of trade on Thursday 7 June 2018, or earlier if an announcement is made to the market.

Quick facts: Imugene Ltd

Price: 0.02 AUD

ASX:IMU
Market: ASX
Market Cap: $72.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

Imugene Limited (ASX:IMU) chief executive officer Leslie Chong updates Proactive Investors on new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine after presenting at the European Society for Medical Oncology World Congress on gastrointestinal cancer in Spain over the...

on 8/7/19

2 min read